MIMEDX Group, Inc.

Home
United States
Atlanta, GA
MIMEDX Group, Inc.

Patients are why we are here. MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. For additional information, please visit www.mimedx.com.

01/15/2026

For hospital outpatient teams navigating OPPS changes, understanding the details matters.

Join Kathleen Schaum for JUST THE FACTS, an educational webinar unpacking the new ruling and what the policy language means in practice.

Facts over speculation. Register now to watch on-demand: https://mimedx.info/Just-The-Facts-OPPS-On-Demand

01/14/2026

Explore the latest casebook featuring real surgical applications of AMNIOEFFECT®, a tri-layer human placental allograft that provides a protective barrier to support the healing cascade.

Each case demonstrates AMNIOEFFECT's real-world outcomes in a variety of surgical applications. See the results for yourself: https://bit.ly/AMNIOEFFECT

01/08/2026

When policy changes, facts matter.
Join reimbursement expert Kathleen Schaum for JUST THE FACTS, an educational webinar focused on the new OPPS ruling—designed to help hospital outpatient teams better understand the policy language and considerations.

No speculation. Just the facts. Register to watch on January 14th, 2026, 12:00 PM EST: https://mimedx.info/JUST-THE-FACTS-OPPS

01/07/2026

For hospital outpatient teams navigating OPPS changes, understanding the details matters.

Join Kathleen Schaum for JUST THE FACTS, an educational webinar unpacking the new ruling and what the policy language means in practice.

⏱️January 14th, 2026 | 12:00 PM EST
Facts over speculation. Register now: https://mimedx.info/JUST-THE-FACTS-OPPS

01/06/2026

AMNIOEFFECT® is an advanced tri-layer placental allograft that provides a protective barrier to support the healing cascade. It is 3x thicker than a dual-layer amnion/chorion allograft to address surgical wounds and provide optimal handling.¹ The product is used in surgical wounds that include:
⬢Debridements
⬢Amputations
⬢Complex incision management
⬢Tendon & ligament repair

Explore where AMNIOEFFECT fits in your surgical toolkit: https://bit.ly/AMNIOEFFECT

1. MIMEDX Internal Report, MM-RD-00116.

01/02/2026

🏥 Rural and Critical Access Hospitals face unique challenges in diabetic care — but with the right strategies, they can lead the way in prevention and early intervention.

Join the National Rural Health Association (NRHA) and MIMEDX for a free educational webinar designed for hospital leaders, clinicians, and wound care teams.

🎙️Speaker: Anthony Iorio, DPM, FACFAS, FAPWHc
💻Register and watch here: https://mimedx.info/NRHA-Webinar

12/31/2025

MIMEDX's advanced treatment options can help patients focus on their lives instead of their wounds. Our skin substitute allografts have been used in many clinical applications including diabetic foot ulcers, venous leg ulcers, Mohs surgery, tendon repair, complex surgical procedures, and more.

Explore our wide range of products and services: https://bit.ly/48rydiW

12/18/2025

New in MIMEDX Connect: Online payments powered by Billtrust are now live. Now clinicians can:
• Make secure payments anytime
• Track balances and billing history
• Streamline office workflows from one portal

Learn more about MIMEDX Connect: https://mimedx.info/4kbGGwX

12/11/2025

EPIFIX®, a protective barrier to support the healing cascade, was compared to autologous tissue in a 5-year retrospective, single-center, peer-reviewed study of 429 patients* undergoing post-Mohs surgery reconstruction in areas such as the face, scalp, and hands.

The study showed that when compared to those treated with autologous tissue, patients treated with EPIFIX achieved:
• Closure 15 days faster on average (p=0.0031)
• A 7.7X reduction in prolonged care on average (p=0.0005)

These outcomes can help streamline patient outcomes and reduce follow-up complexity.

Learn more about the study: https://mimedx.info/44UGaOG

Reference: Toman J, et al. J Drugs Dermatol. 2025;24(5):217–223.
*(1:2 match (143 DHACM, 286 SOC)
The information provided is for education only and is not meant to direct clinical decision making. Refer to the IFU for application and intended use.

12/10/2025

The future of surgical care is here — and we’re inviting distributors to be part of it.
MIMEDX continues to expand its footprint in advanced surgical tissue products and is seeking 1099 surgical agents with strong OR-based relationships to grow their portfolios with a trusted leader in innovation, integrity, and outcomes.

MIMEDX offers placental-based and xenograft surgical products supported by strong nationwide GPO and IDN contracts and partnerships, providing exceptional access to the OR.

Preferred experience includes Spine, Ortho, Neuro, Colorectal, GYN, and Foot & Ankle specialties, among others.

Partner with a trusted name in surgical innovation and patient care.
Contact Frank Braly at fbraly@mimedx.com, Bill Timony at btimony@mimedx.com, or contact us here: https://mimedx.info/Contact-Us

12/09/2025

Did you know that MIMEDX has the most Level I RCTs of any placental allograft company? With seven RCTs demonstrating the safety and efficacy of EPIFIX® and EPICORD®, we are empowering clinicians with evidence to enhance patient outcomes.

Learn more about the science behind our advanced wound and surgical solutions: https://bit.ly/3v2A52R

12/03/2025

Did you know? MIMEDX partner, WoundGenex, offers the Premier Graft Program to make advanced wound care more accessible by offering practices support with documentation, reimbursement, and payment timing.

🔗Learn more in our overview video featuring our WoundGenex partners: https://mimedx.info/WoundGenex-PGP-Overview-Video

Address

Atlanta, GA

Telephone

+17706519100

Website

http://www.mimedx.com/

Alerts

Be the first to know and let us send you an email when MIMEDX Group, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Atlanta?